Carregant...
FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro
Although regorafenib has demonstrated survival benefits in patients with metastatic colorectal and gastrointestinal stromal tumors, no proven biomarker has been identified for predicting sensitivity to regorafenib. Here, we investigated preclinical activity of regorafenib in gastric and colorectal c...
Guardat en:
| Publicat a: | Mol Oncol |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6026866/ https://ncbi.nlm.nih.gov/pubmed/29573334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12194 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|